



BIOTECH · HEALTHTECH · MEDTECH

STRATEGY, INVESTMENT, PARTNERING &  
COMMERCIALISATION FOR LIFE SCIENCE  
EXECUTIVE LEADERS

7th Annual

1-5 February, 2021  
Delivered Virtually

[www.lsxleaders.com/world](http://www.lsxleaders.com/world)  
#LSXWorld @lsxleaders

Organised by:



LSX World Congress

1-5 February 2021

# LSX World Congress

For 6 years, the LSX World Congress has been bringing together the executives that matter to the future of healthcare and life science strategy, investment, partnering and deal making.

LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly listed life sciences giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.

The industry's c-suite will be joined by the sector's most active investors, pharma and health tech BD&L teams, R&D leaders, KOLs and top tier service companies who are moving the sector forward.

In an industry as dynamic as the life science and healthcare sector, LSX World Congress brings the people who are tackling the biggest

challenges in the industry today, and helps answer the question; where to next and how do we get there?

With our relentless focus on quality peer-to-peer discussion, high-level networking and partnering, intimate conference formats and a vetted, high-calibre audience, we help you **connect with purpose™**.

In 2021, the event will be a virtual experience incorporating all the same features of the usual physical meeting, but spread across a full week. The event also welcomes **Healthtech** Leaders underneath the LSX World Congress banner, joining **Biotech** Leaders and **Medtech** Leaders.



[www.lsxleaders.com/world](http://www.lsxleaders.com/world)

#LSXWorld @lsxleaders

# Who attends?

## Biotech

Drug discovery, pre-clinical, clinical & on-the-market therapeutics

## Medtech

Devices, surgical, diagnostics, implantables

## Healthtech

Digital health, DTx, deep tech, databases, applications, wearables

## Commercial Leaders

Big Pharma, Big Medtech, Big Tech

## Investors

Angel, VC, CVC, Family Office, PE, Institutional

## Advisors & Solution Providers

Consultancy, Professional Services, Contract Services, IP & Law,  
Investment Banks & Financial Services, PR/IR

## Healthcare Industry Stakeholders

Academia, TTOs, Payers, Providers, Reimbursors



## Platinum Partners





Gold Partners



Silver Partners



Pharma Digital Partner

**Deloitte.**

Knowledge Partner

**McKinsey  
& Company**

Bronze Partners



Supporting Partners

| Citigate Dewe Rogerson







**PLUGANDPLAY APAC**





# Week at a Glance

Monday 1 February	Tuesday 2 February			Wednesday 3 February			Thursday 4 February			Friday 5 February
<div> IPO BOOTCAMP</div> <div>&amp; 1:1 Partnering</div>	<div> BIOTECH LEADERS</div> <div>Capital Markets &amp; Investment</div>	<div> HEALTHTECH LEADERS</div> <div>Life Science &amp; Digital Health Partnerships</div>	<div> MEDTECH LEADERS</div> <div>Design, Development &amp; Digitisation</div>	<div> BIOTECH LEADERS</div> <div>Partnerships &amp; Deal-Making</div>	<div> HEALTHTECH LEADERS</div> <div>Capital Markets &amp; Investment</div>	<div> MEDTECH LEADERS</div> <div>Capital Markets &amp; Investment</div>	<div> BIOTECH LEADERS</div> <div>Capital Deployment &amp; Commercialisation Strategy</div>	<div> HEALTHTECH LEADERS</div> <div>Payers, Providers &amp; Reimbursement</div>	<div> MEDTECH LEADERS</div> <div>Market Access &amp; Commercialisation Strategy</div>	1:1 Partnering
<div> CLINICAL STRATEGIES WORKSHOP</div>	<div> PUBLIC CEO FORUM</div>			<div> PHARMA DIGITAL LEADERS FORUM</div>	<div> PRIVATE CEO FORUM</div>	<div> PHARMA BD LEADERS FORUM</div>	<div> STARTUP CEO FORUM</div>			

1:1 Partnering (24 hours all week)


1:1 Partnering (24 hours all week)

# 1:1 Video Partnering

Social distancing practices around the world have shown just how productive digital work methods can be. Our goal remains for you to establish new partnerships and find the best connections.


*“Your platform is by far the best and most efficient, user-friendly and powerful platform I have ever used for a virtual conference. The filtering system works perfectly. The data is entered correctly (don’t take this for granted) and the logic is programmed correctly.”*  
**Moshe Lebowitz, CEO, Healables Digital Health**

## AI-driven matchmaking



All attendees are listing with profiling criteria given at the time of registration. Attendee profiles are fully customisable and give you a unique insight into why the company is attending and what they hope to achieve. With your completed profile the software will match you with executives aligned to your search criteria. These are rated/ranked in order of importance allowing you to focus your time.


## Personal schedule



1:1 Partnering runs 24hrs from 1st-12th February, to accommodate all time zones and begins at 8am on Day 1. With literally hundreds of 30mins slots available you’ll not have any problems finding times to suit both parties.


# 1:1 Video Partnering

## Private & secure




Video and audio-enabled meeting platform is tried and tested. Collaborate & communicate effortlessly as if you were in the same room.

## Chance meetings



We realise that some of the most valuable connections happen through serendipitous and chance meetings. For this reason, there will be dedicated networking sessions built into the virtual schedule allowing you to engage in live text chat, before deciding if you’d like to arrange a more formal meeting through the partnering system.

## Intuitive platform



We’re confident we have the platform to deliver equal, if not even greater, value as attending a physical event. It’s now been tried and tested all year by LSX and a peer group of event professionals and is constantly developing to give you the best experience.




# Biotech Speakers



**Samana Brannigan**  
Innovation Lead and  
Investor Relations,  
Innovate UK



**Sean Marett**  
CBO, BioNTech



**Philippe Lopes-Fernandes**  
EVP and CBO, Ipsen



**Aradhana Sarin**  
CFO, Alexion  
Pharmaceuticals



**Elizabeth Mily**  
EVP BD, BMS



**Ben Thorner**  
SVP & Head MRL BD  
& Licensing, Merck  
& Co




**Alex Hamilton**  
Partner, Syncona



**Yuehua Cong**  
Exec Director, Head  
of Europe, Simcere  
Pharmaceutical  
Group



**Jorge Santos da Silva**  
Partner, McKinsey &  
Company



**Douglas Abrams**  
Managing Director,  
Expara




**Aditya Puri**  
Partner Investments,  
Xeraya Capital




**Jasper Bos**  
SVP and Managing  
Director, M Ventures



**Laia Crespo**  
Head of Europe,  
Sanofi Ventures



**Adam Houghton**  
VP and Head, AbbVie  
Ventures



**Nick Ibery**  
General Partner, NCL  
Technology Ventures



**Maria Dahl**  
COO and Head of  
Europe, Innovent Bio



**Guillaume Vignon**  
SVP BD, Beigene




**Phil L'Huillier**  
Head of BD, Europe,  
European Innovation  
Hub, MSD



**Teresa Lavoie**  
Principal, Fish &  
Richardson



**Shu Joshi**  
MP, LSV Capital  
& Co-Chair of  
Global Investment  
Committee, Xhealth  
Innovation Labs



**Jürg Eckhardt**  
SVP and Head of  
Leaps by Bayer,  
Bayer



**Carl Engleman**  
Vice President, Cello  
Health Consulting



**Ted Fjällman**  
CEO, Prokarium




**Ben Hohn**  
Principal - BD,  
Pipeline and  
Launch Strategy, ZS  
Associates


# Biotech Speakers




**Susanna Obad**  
Global Business  
Development  
Director, Roche  
Partnering




**Cody Powers**  
Principal Strategy  
& Advisory, ZS  
Associates



**Sara Secall**  
Partner, Inveready



**Jason Foster**  
CEO, Ori Biotech




**Miriam Frieden**  
Vice President S&E,  
Novo Nordisk




**Renée Aguiar-Lucander**  
CEO, Calliditas  
Therapeutics



**Su-Peung Ng**  
VP Global Medical  
Head, COVID-19  
Taskforce Leader,  
Sanofi Pasteur



**Sharon Cunningham**  
Co-Founder and  
CEO, Shorla Pharma



**Ed Saltzman**  
Executive Chairman,  
Cello Health  
BioConsulting



**Johnston Erwin**  
VP Corporate  
Business  
Development, Eli Lilly




**Tim Luker**  
VP Lilly New  
Ventures & Emerging  
Technology, Eli Lilly




**Andrey Ostrovsky**  
Former CMO of US  
Medicaid Program;  
MP, Social Innovation  
Ventures



**Darrin Disley**  
CEO, Mogrify



**Lea von Bidder**  
CEO & Co-founder,  
Ava



**Liz Barrett**  
CEO, Urogen



**Erik van den Berg**  
CEO, AM-Pharma



**Chen Yu**  
Managing Partner,  
TCG Crossover Fund




**Caroline Barelle**  
Co-Founder and  
CEO, Elasmogen




**Beth Fordham-Meier**  
VP BD & Head,  
Partnering Strategy  
Practice, Cello Health  
BioConsulting



**Yochi Slonim**  
CEO, Anima Biotech



**Thibaut Roulon**  
Investment Director,  
BpiFrance



**Hans Schambye**  
CEO, Galecto



**Denise Scots Knight**  
CEO, Mereo  
BioPharma



**Rhony Aufdenblatten**  
Head of Commercial  
Development, Lonza  
Pharma & Biotech



# Biotech Speakers



**Adam Keeney**  
CEO, NodThera



**John Cassidy**  
Principal, Aris  
Bioscience



**Naseem Amin**  
CEO, gmp-orphan



**Clive Cookson**  
Science Editor,  
Financial Times



**Laurie Smaldone  
Alsup**  
CSO/CMO, NDA  
Group



**Steffen Thirstrup**  
Director, NDA  
Regulatory Advisory  
Board, NDA Group



**Madeleine  
Armstrong**  
News Editor, Vantage



**Angela Tyrell**  
SVP, Longevity  
Leaders



**Sharon Benzeno**  
CBO, Adaptive  
Biotech



**Lucie Ellis**  
Executive Editor, In  
Vivo



**Mirko Scherer**  
CEO, CoFeS China



**Axel Kullick**  
Manager  
International Market  
Development, Invest  
Region Leipzig



**Adam Kostyal**  
SVP, Nasdaq



**Valerie Vanhooren**  
Co-Founder  
and CEO, ONA  
Therapeutics



**Eliot Forster**  
CEO, F-star  
Therapeutics



**Christine Baker**  
CBO, Hookipa  
Pharma



**Brian Yang**  
Senior Writer & China  
Head, Scrip



**Nanna Lüneborg**  
Partner, Novo  
Ventures



**Neil Clark**  
CEO, Destiny Pharma



**Robbie McLaren**  
Partner, Latham &  
Watkins



**Fiona MacLaughlin**  
Senior Director,  
Johnson & Johnson  
Innovation JJDC Inc



**Kieran Rooney**  
VP, Strategic  
Alliances and  
Licensing, Amryt  
Pharma



**Bill Hicks**  
Co-chair Securities  
& Capital Markets  
Group, Mintz



**Jan Mattsson**  
Chief Scientific  
Officer and Co-  
Founder, Albireo


# Biotech Speakers



**Jason Duncan**  
Chief Legal Officer  
and General Counsel,  
Albireo



**Thomas Tradler**  
Head of BD,  
Fraunhofer Institute  
for Cell Therapy and  
Immunology




**Barbara Weigert**  
Project Manager,  
Saxony Economic  
Development  
Corporation



**Frank Rahmani**  
Partner, Sidley Austin



**Matt Cardinal**  
Principal, Halloran  
Consulting Group



**Cornelia Kroeger**  
Senior Consultant,  
Halloran Consulting  
Group



**Monika Vnuk**  
VP Worldwide  
Business  
Development, Pfizer



**Regina Hodits**  
Managing Partner,  
Wellington Partners



**Steven Powell**  
CEO, eTheRNA



**Andrew Parratt**  
VP Commercial  
Planning and  
Operations, Karuna  
Therapeutics




**Edward van Wezel**  
Managing Partner,  
Biogeneraiton  
Ventures



**Wouter Joustra**  
General Partner,  
Forbion



**Matthew Gline**  
CFO, Roivant



**Ed Kaye**  
CEO, Stoke  
Therapeutics



**Alexandra Zemp**  
Partner, McKinsey &  
Company



# Healthtech Speakers



**Rana Lonnen**  
Head of Search and  
Evaluation, Strategic  
Capital, Novartis



**Bruce Meadows**  
Head of Investments,  
Takeda Digital  
Ventures



**Lara Koole**  
Founder and Partner,  
Philips Ventures




**Jackie Hunter**  
Board Director,  
BenevolentAI



**Abraham Heifets**  
Co-Founder and  
CEO, Atomwise




**Martin-Immanuel  
Bittner**  
Co-Founder and  
CEO, Arctoris



**Charles Fisher**  
Founder and CEO,  
Unlearn.AI



**Lisa Alderson**  
CEO, Genome  
Medical



**Jesaja Brinkmann**  
CEO, Cara Care



**Megan Coder**  
Executive Director,  
Digital Therapeutics  
Alliance



**Zach Henderson**  
CCO, Glooko



**Adrian Cassidy**  
Global Head of Real-  
World Evidence,  
Novartis




**Carolyn Magill**  
CEO, Aetion



**Lori Evans Bernstein**  
President and Chief  
Operating Officer,  
HealthReveal




**Lisa Bookwalter**  
Director, Twitter  
Client Solutions,  
Health, Twitter



**Jennifer Esposito**  
VP Health, Magic  
Leap



**Mark Davies**  
Chief Medical Officer,  
EMEA, IBM Watson  
Health



**Amir Zur**  
Sr. Director, Head of  
Products of Digital  
Health, Teva




**Alex Aravanis**  
Chief Technology  
Officer, Illumina, Co-  
Founder, Grail



**Clara Campàs**  
Co-Founder and  
Managing Partner,  
Asabys Partners



**David Christie**  
Head of Digital  
Strategy  
Implementation, CSL  
Behring



**Jessica Federer**  
Partner, Boston  
Millennia Partners



**Peter Finnie**  
Partner, Potter  
Clarkson




**Michael Greeley**  
General Partner, Flare  
Capital

# Healthtech Speakers



**Dennis Grishin**  
Co-Founder, Nebula  
Genomics



**Lauren Li**  
Head of Digital  
Health, Ipsen



**Karen Murphy**  
Chief Innovation  
Officer, Geisinger



**Josh Raysman**  
Vice President Digital  
Innovation Lab, Pfizer



**Laurent Schockmel**  
CEO, Antidote.me



**Steve Tolle**  
Partner, HLM  
Ventures



**Glen Tullman**  
Founder and  
Chairman, Livongo



**Henrik Matthies**  
MD, Health  
Innovation Hub,  
Federal Ministry of  
Health, Germany



**Rajni Aneja**  
Head of Digital  
Transformation and  
Strategy, Sanofi




**Tryggvi  
Thorgeirsson**  
CEO and Co-  
Founder,  
SidekickHealth




**Daniel Forslund**  
Chairman Innovation  
& Development  
Committee, Region  
Stockholm




**Corbin Petro**  
CEO, Eleanor Health



**Brian O'Connor**  
Chair, European  
Connected Health  
Alliance



**Liam Kaufman**  
CEO, Winterlight  
Labs



**Gottfried Ludewig**  
Digitisation of Public  
Health, Federal  
Ministry of Health,  
Germany



**Peggy Wang**  
Chairman, Mitrassist




**Päivi Sillanaukee**  
Ambassador for  
Health & Wellbeing,  
Ministry for Foreign  
Affairs, Finland



**Fredrik Strömberg**  
Senior Director  
Northern Europe,  
Nobel Biocare




**Ian Crosbie**  
CEO, Sequana  
Medical




**Ann Aerts**  
Head Novartis  
Foundation, Novartis



**John Bertrand**  
CEO, Digital  
Diagnostics



**Tobias Silberzahn**  
Partner, McKinsey



**Joanne Hackett**  
General Partner, IZY  
Capital



**Inga Deakin**  
Principal, Draper  
Esprit



# Healthtech Speakers



**Robert Garber**  
Partner,  
7wireventures



**Nick Scott-Ram**  
Managing Director –  
Discovery Sciences,  
Sensyne Health



**Heather Roxborough**  
Partner, Optum  
Ventures




**Neil Sebire**  
Chief Research  
Information Officer,  
Great Ormond Street  
Hospital



**Vindell Washington**  
Chief Clinical Officer,  
Verily Life Sciences



**Hakim Yadi**  
CEO, Closed Loop  
Medicine



**Rachel Ford Hutman**  
Founder and CEO,  
Ford Hutman Media



**Tom Waller**  
SVP Advanced  
Innovation, lululemon



**Kristi Henderson**  
SVP Innovation  
Telehealth, Optum



**Tim Gronniger**  
CEO, Caravan Health



**Sarah Elizabeth  
Richards**  
Health and Science  
Journalist, WIRED



**John Hodgson**  
Independent  
Consultant



**Tina Tan**  
Executive Editor,  
FirstWord Healthtech



**David Germonpre**  
Investment Partner,  
MTIP



**Adam Dakin**  
Managing Director,  
Dreamit Ventures




**Dan Kendall**  
Managing Director,  
Mission Based Media



**Bill Aronson**  
COO, Artificial  
Intelligence Research  
Group



**Lala Gregorek**  
Analyst, Trinity Delta



**Elizabeth Cairns**  
Medtech Reporter,  
Vantage



**Gil Rabbie**  
Digital Solutions  
and Capability  
Development Leader,  
Boston Scientific



**Jay Yin**  
Partner, Bioventure



**Niamh Mckenna**  
CIO, NHS Resolution



**Daniel Wang**  
Managing Partner,  
TUSPARK Capital  
Management



**Catherine  
Longworth**  
Web Editor,  
pharmaphorum

# Healthtech Speakers



**Thom Rasche**  
Managing Partner,  
Earlybird Capital



**Chris Scales**  
Director of Strategy  
and Insight, Star



**Andrea Jackson**  
Director, Northpond  
Ventures




**Katherine Li**  
CEO, BrainBase Line




**Rajeev Ronanki**  
SVP and Chief Digital  
Officer, Anthem



**Mikki Nasch**  
Co-Founder &  
VP Business  
Development,  
Evidation Health



**Jennifer Esposito**  
VP Health, Magic  
Leap



**Adam Landman**  
Chief Information  
& Digital Officer,  
Brigham & Women's  
Hospital



# Medtech Speakers



**Didier Deltort**  
President EMEA,  
Zimmer Biomet



**John Milad**  
CEO, Quanta



**Marc Julien**  
Co-CEO, Diabeloop



**Sergio Levi**  
VP and Head of  
Strategic Alliances,  
Philips



**Seamus Browne**  
Head of Industry  
Partnerships, Royal  
College of Surgeons



**Chas Taylor**  
Co-Founder  
MedNova, Novate  
Medical, former CEO,  
Veryan Medical



**Charity Kufaas**  
VP BD and Strategy,  
Medtronic



**Tamir Meiri**  
SM, Venture  
Investments, Johnson  
& Johnson Innovation  
- JJDC, Inc.




**Sascha Alilovic**  
Managing Partner,  
SHS Capital



**Rainer Strohmenger**  
Managing Partner,  
Wellington Partners



**Ari Silverman**  
Partner, Mavie  
Technologies




**Jessica Federer**  
Partner, Boston  
Millennia Partners



**Michael Greeley**  
General Partner, Flare  
Capital




**Steve Tolle**  
Partner, HLM  
Ventures



**Christian Weiß**  
Managing Partner,  
Heal Capital



**Katrin Geyskens**  
Partner, Capricorn  
Partners



**Michael Niddam**  
Co-Founder, Kamet  
Ventures



**Fernando Pacheco**  
Investment Director,  
Endeavour Vision




**Daniel O'Mahony**  
Partner, Seroba Life  
Sciences



**Xavier Bertrand**  
VP Healthcare  
Services and  
Alliances, Boston  
Scientific




**Finn Haley**  
VP Corporate  
Development,  
Edwards Lifesciences



**Jeffrey Shuren**  
Director, CDRH, FDA




**Steve Swinson**  
Chairman, Tibbiiyah  
Holdings, Comphya



**Rupert Winckler**  
Head of EMEA BD,  
Medical Systems  
Division, Olympus SE  
& Co.


# Medtech Speakers



**Amir Zur**  
Head of Digital  
Health Products, Teva




**Fredrik Strömberg**  
Senior Director  
Northern Europe,  
Nobel Biocare



**Ian Crosbie**  
CEO, Sequana  
Medical



**Lea Von Bidder**  
CEO, Ava



**Claire Woodthorpe**  
COO and VP Europe,  
Lightpoint Medical



**Robert Garber**  
Partner  
7wireventures




**Heather Roxborough**  
Partner, Optum  
Ventures



**Tina Amini**  
Medical Device  
Division Director,  
NDA Group




**Hakim Yadi**  
CEO, Closed Loop  
Medicine



**Rachel Ford Hutman**  
Founder and CEO,  
Ford Hutman Media



**Rob Ten Hoedt**  
President EMEA,  
Medtronic



**Elizabeth Cairns**  
Medtech Reporter,  
Vantage



**David Braun**  
Head of Connected  
Health & Medical  
Device, Merck Group



**Tina Tan**  
Executive Editor,  
FirstWord Healthtech



**David Geronpre**  
Investment Partner,  
MTIP



**Dan Kendall**  
Managing Director,  
Mission Based Media




**Andy Smith**  
Analyst, Equity  
Development



**Adam Dakin**  
Managing Director,  
Dreamit ventures



**Franc Gregori**  
Analyst, Trinity Delta




**Catherine Longworth**  
Web Editor,  
pharmaphorum



**Jay Yin**  
Partner, Bioventure



**Daniel Wang**  
Managing Partner,  
TUSPARK Capital  
Management



**Peggy Wang**  
Chairman, Mitrassist



**Thom Rasche**  
Managing Partner,  
Earlybird Capital



# Medtech Speakers




**Chris Scales**  
Director of Strategy and Insight, Star



**Luc Behr**  
DVM, PhD, Co-Founder and Scientific Director, IMMR




**Tonya Dowd**  
Reimbursement, Health Economics and Market Access, MCRA




**John McDermott**  
Senior Director, Reimbursement Strategy, MCRA



**Abigail Allen**  
VP of Clinical Affairs, MCRA



**Andrea Jackson**  
Director, Northpond Ventures



**Kenneth Strople**  
President, Fusion Healthcare Management, LLC



**John Fox**  
Chief Boundary Spanner, Foxworthy Healthcare Consulting




**Tryggvi Thorgeirsson**  
CEO and Co-Founder, SidekickHealth



**Sotiris Rompas**  
Senior Director, Huron



**Jon Speer**  
Founder, Greenlight Guru



**John Bertrand**  
CEO, Digital Diagnostics

# Satellite Forums



**Monday 1 February 15:00 GMT**  
*An 1.5hr intimate, interactive forum in which a leading CRO partner hosts an intimate group of biotech CxOs to discuss cost-effectively developing their clinical programmes.*



**Tuesday 2 February 15:00 GMT**  
*A Chatham House Rule, invite-only forum for CEOs, CFOs, CBOs and Chairs of listed life science and healthcare companies. The forum will feature peer-reviewed CEO and partner case studies and an interactive general discussion discussing the most pressing challenges, and exciting opportunities, for the participants. The Public CEO Forum is open only to biotech companies listed on the public markets.*



**Wednesday 3 February 15:00 GMT**  
*An invite-only leaders' 2hr roundtable forum, in which those leading the charge on digital transformation and innovation initiatives at global pharma share their experiences, discuss their collective challenges and look ahead at future developments and actionable outcomes.*



**Wednesday 3 February 15:00 GMT**  
*A Chatham House Rule, invite-only forum for CEOs, CFOs, CBOs and Chairs of private life science and healthcare companies. The forum will feature peer reviewed c-level and partner case studies, and an interactive general discussion. The Private CEO Forum is only open to post-series A private biotech companies.*



**Thursday 4 February 15:00 GMT**  
*An invite-only leaders' roundtable forum for global heads of Pharma business development and M&A, in which the biggest deal-makers from global pharma share their experiences, discuss their collective challenges and look ahead at future developments and actionable outcomes.*



**Thursday 4 February 15:00 GMT**  
*A Chatham House Rule, invite-only forum for CEOs of biotech, medtech and healthtech startups. The forum will feature peer-reviewed c-level and partner case studies and an interactive general discussion focussed on overcoming the challenges faced by startups in the healthcare space. The Startup CEO Forum is only open to pre-series A private companies and spin-outs from our TTO partners.*






Monday, February 1 - all times in GMT

11:00	Keynote Address: The Current State Of The Nordic IPO Market
11:20	Roundtable: Determining And Defining Your IPO Strategy
12:00	IPO Case Study
12:40	Lunch Break
13:30	1:1 Expert Consultations
17:00	Close Of IPO Bootcamp

Co-hosted by:



1:1 Partnering (24 hours all week)



BIOTECH  
LEADERS

Day 1 - IPO Bootcamp

Day 2 - Capital Markets & Investment

Day 3 - Partnerships & Deal-Making

Day 4 - Capital Deployment & Commercialisation Strategy

Day 5 - 1:1 Partnering



Tuesday, February 2 - all times in GMT

09:00	<b>Welcome Address</b>  Josh Dance, SVP, LSX
09:05	<b>Keynote Presentation: The Biotech Wave – Where Do We Go Next?</b>  <ul style="list-style-type: none"><li>2020 was an unprecedented year for biotech, with funding, deals and IPOs reaching highest level worldwide - analysis of 2020 financing and deals</li><li>The start of 2021 has been promising and shows the continued strong fundamentals of the sector - key drivers</li><li>The next wave of science &amp; innovation is coming, such as the convergence of biology, digital and technology - where are we heading?</li></ul> Jorge Santos da Silva, Partner, McKinsey & Company Alexandra Zemp, Partner, McKinsey & Company
10:00	<b>Morning Keynote Panel: China and Beyond – Asian Investment in Innovation</b>  <i>As the global dynamics of the life sciences industry continue to evolve and change, Asian innovation and investment into local and global innovation is a clear trend. China has been leading the way making significant investment in its own growing cohort of companies, as well as across the US and increasingly in Europe. However, investors from other Asian countries are also investing locally to help develop startups, and contributing to the east to west capital flow, be it strategic or purely financial. Investors from across Asia discuss how the rise in the East is just beginning, and the future of the Asian investment and innovation landscape.</i>  Moderator: Mirko Scherer, CEO, CoFeS China Douglas Abrams, Managing Director, Expara Aditya Puri, Partner Investments, Xeraya Capital Shu Joshi, Managing Partner, LSV Capital

1:1 Partnering (24 hours all week)

11:00	<b>Panel: Corporate Clout In Biotech Ventures</b>  <i>Be it through strategic or purely financial models, CVC is playing an ever-growing role in biotech investment. While strategic CVC reflects the continuation of the long-term trend toward supplementing and even supplanting in-house R&amp;D through venture capital, other CVC funds are financial VC successes in their own right, whilst also having big pharma expertise and contacts on tap for company support. Executives from corporate venture discuss the 'multiplier effect' of corporate venture attracting additional investors and strong syndicates, the evolving role of corporate venturing in life sciences and global investment.</i>  Moderator: Lucie Ellis, Executive Editor, In Vivo Jasper Bos, SVP and Managing Director, M Ventures Laia Crespo, Head of Europe, Sanofi Ventures Adam Houghton, VP and Head, AbbVie Ventures Jürgen Eckhardt, SVP and Head, Leaps by Bayer
12:00	<b>Panel: Accelerating Innovation Through Early-Stage Investment</b>  <i>Funding of early stage biotech companies has never been more crucial as scientific breakthroughs and new modalities show huge promise for areas of unmet medical need. As rounds are getting bigger, and early stage capital increasingly comes from diverse geographies and syndicates, how are investors seeing the future of early stage investment? Some of the most active and exciting early-stage investors, backing the next generation of innovators, discuss how the current climate has influenced investment decisions, with money and exits seemingly readily available, and the advice they are giving to portfolio companies and investment prospects about securing the capital they need in the current disrupted world.</i>  Moderator: Samana Brannigan, Innovation Lead and Investor Relations, Innovate UK Alex Hamilton, Partner, Syncona Sara Secall, Partner, Inveready Thibaut Roulon, Investment Director, BpiFrance John Cassidy, Principal, Arix Bioscience
13:00	<b>Panel: Making History With Biotech's Listing Boom – KSFs and Virtual Roadshows</b>  <i>Far from the doom-and-gloom of other industries, 2020 proved a historic window for public offerings, smashing all records in terms of volume of listings and overall capital poured into the sector. While the model of the special purpose acquisition company (SPAC) made huge headlines, many growing companies ready for the move public took the traditional route and made history. Executives of these companies discuss the decision and timing of their offerings, the key success factors in their successful listing, and managing roadshows, investor meetings and the listing process in the virtual world.</i>  Moderator: Frank Rahmani, Partner, Sidley Austin Eliot Forster, CEO, F-star Therapeutics Adam Kostyal, SVP, Nasdaq Hans Schambye, CEO, Galecto

1:1 Partnering (24 hours all week)

15:00 Presentation And Panel: Investing In Infectious Disease - How Will The Covid Pandemic Transform The Development, Commercialisation, And Partnering Landscape?

Historically, levels of investment and pipeline activity infectious diseases have paled in comparison to other areas due to development and commercialisation challenges. The COVID-19 pandemic has brought infectious diseases back into sharp focus and amidst a surge of investment back into the sector which has transformed the current landscape. But is this just a one-time spike for the current pandemic or a longer-term shift in the 'post-pandemic' era? After an introductory scene-setting presentation, executives and experts discuss the past, current and future landscape for infectious diseases in terms of investment, development, commercialisation and policy.

- What are the historical challenges that have limited investment in both development and commercialisation in infectious disease?
- What do we believe the COVID pandemic will change – in terms of urgency, policy, and underlying thesis for investment in the space?
- Which areas are more ripe for investment and how can a compelling case be made for the space to investors and for policy makers?
- What role do we expect transactions to play in the space – in terms of discovery, development, and commercialization – and do recent events change what players are likely to enter new deals?

Presenter and moderator: **Cody Powers**, Principal Strategy & Advisory, **ZS Associates**  
**Christine Baker**, Chief Business Officer, **Hookipa Pharma**  
**Neil Clark**, CEO, **Destiny Pharma**  
**Andrew Parratt**, VP Commercial Planning and Operations, **Karuna Therapeutics**

16:00 Afternoon Keynote Panel: Investment In The Pandemic Era – Evolving Strategies Or Masking Established Fundamentals?

As we enter a new year, it's clear that the world will never quite be the same again, but will the strategies of the most influential investors? Are these evolving or has the pandemic simply accelerated interest and capital flow in the space based on the established fundamentals and great opportunities that exists in life sciences and healthcare investment. Industry leading investors from both sides of the Atlantic discuss the impact of the 2020 disruption and the financing landscape in 2021 and beyond.

Moderator: **Bill Hicks**, Co-chair Securities & Capital Markets Group, **Mintz**  
**Johnston Erwin**, VP Corporate Business Development, **Eli Lilly**  
**Regina Hodits**, Managing Partner, **Wellington Partners**  
**Wouter Joustra**, General Partner, **Forbion**  
**Chen Yu**, Managing Partner, **TCG Crossover Fund**  
**Stephanie Sirota**, Partner and Chief Business Officer, **RTW Investments**

17:45 Virtual Drinks Reception

1:1 Partnering (24 hours all week)

Wednesday, February 3 - all times in GMT

09:00 Welcome Address

**Josh Dance**, SVP, **LSX**

10:00 Keynote Panel: Coming of Age – In and Out Licencing, Partnering and Deal-Making in China

Chinese innovation is flourishing and 2020 saw a huge surge in IPOs, M&A and deal-making in the Chinese biotech sector and with global partners. Both in and out licencing deals show the increasing influence and coming of age as a major global player after years of investment. Executives and deal-makers from Chinese companies discuss successful win-win deals, navigating the ecosystem, the opportunities that exist for Western companies and the growth of the ecosystem in 2021 and in the future.

Moderator: **Brian Yang**, Senior Writer & China Head, **Scrip**  
**Guillaume Vignon**, SVP BD, **Beigene**  
**Maria Dahl**, COO and Head of Europe, **Innovent Bio**  
**Yuehua Cong**, Executive Director, Head of Europe, **Simcere Pharmaceutical Group**

11:00 Presentation: Saxony! – Building Europe’s Cell And Gene Therapy Hub

The German Free State of Saxony is an internationally recognised leader in immunological and genetic research as well as the development and patient application of novel cell and gene therapies. Biomedical clusters in the cities of Dresden, Leipzig and Chemnitz complement each other brilliantly in terms of basic research, applied research, clinical trials, and patient care. Going forward, Dresden, Leipzig and Chemnitz will further integrate to create Germany's cluster champion for “living medicines” – SaxoCell. By bringing together the strengths of Saxony's top research institutes, medical institutions, and industries, SaxoCell will develop production methods and applications for new “living medicines” that will make the costs for healthcare systems affordable and enable broader medical applications and thus a realistic economic model with high value-added potential.

- The strengths and opportunities that the state's life sciences ecosystem presents to international players
- First-hand insights into one of Germany's most dynamic life sciences environments
- Business support services and incentives available

**Axel Kullick**, Manager International Market Development, **Invest Region Leipzig**  
**Thomas Tradler**, Head of BD, **Fraunhofer Institute for Cell Therapy and Immunology**  
**Barbara Weigert**, Project Manager Inward Investment, **Saxony Economic Development Corporation**

1:1 Partnering (24 hours all week)

12:00 Panel: United Industry Front - Partnerships To Defeat The Pandemic

Biopharma has rarely been under such sharp global focus brought about by the COVID-19 pandemic. As the industry responded swiftly, information sharing, collaboration and resource pooling agreements became key, putting aside any wider competition and developing partnerships to expedite potential vaccines and treatments. Executives from some of the companies working in partnership to as part of the fight against the pandemic discuss how far they have come in their partnerships, the importance of the united industry front and, and what lessons can be learned from these agreements for the industry moving forward.

Moderator: **Clive Cookson**, Science Editor, **Financial Times**  
**Sean Marett**, CBO, **BioNTech**  
**Su-Peing Ng**, VP Global Medical Head, COVID-19 Vaccines Taskforce Leader, **Sanofi Pasteur**  
**Monika Vnuk**, VP Worldwide Business Development, **Pfizer**

13:00 Panel: Early-Stage Partnering For Broad Platform Companies

Compelling scientific innovation and record-breaking IPOs and financings have led to a resurgence in the appeal and valuations of broad platform biopharma companies. But to fulfill their promise and justify investor confidence, platform companies must be clever and calculated in advancing portfolio development and partnering strategies. Early partnering is an important and arguably essential strategy to validate a technology platform and secure “nondilutive” financing. But deals have consequences, and not all are good. Early deals can be especially costly and constraining if not thoughtfully pursued and structured. Moreover, large pharma, which has long been seen as bringing value in a deal for their development and commercial savvy, lacks compelling experience and track records with commercializing “products” based off of complex platforms including Adoptive Cellular Therapies (ACT) and other types of Advanced Therapeutics like gene therapies and rare and monogenic disease therapies. In this panel, biopharma executives and dealmakers will discuss ways to leverage early-stage partnering to validate platforms and position platform companies for growth and success while avoiding “seller’s remorse.”

Moderator: **Ed Saltzman**, Executive Chairman, **Cello Health BioConsulting**  
**Beth Fordham-Meier**, VP BD & Head, Partnering Strategy Practice, **Cello Health BioConsulting**  
**Yochi Slonim**, CEO, **Anima Biotech**  
**Sharon Benzeno**, CBO, **Adaptive Biotech**  
**Adam Keeney**, CEO, **NodThera**

14:00 Panel: Early-Stage Pharma Partnering - Strategy Change or Just the New Normal?

As breakthrough science continues to come from emerging biotech, academia and increasingly AI-driven companies bringing tech expertise to R&D, the dynamics of innovation continue to evolve. The size, scale, expertise and connections of big pharma is still critical to the ecosystem, but are strategies changing? Has the disruption of the pandemic just made sourcing and connecting with potential partners temporarily more challenging, or has it affected partnering strategy and created a new normal? Pharma execs discuss how they are supporting innovation, sourcing and forming networks, and continuing to work to form win-win deals to partner with next wave biotechs.

Moderator: **Madeleine Armstrong**, News Editor, **Vantage**  
**Phil L’Huillier**, Head of BD, Europe, European Innovation Hub, **MSD**  
**Susanna Obad**, Global Business Development Director, **Roche Partnering**  
**Miriam Frieden**, Vice President S&E, **Novo Nordisk**  
**Tim Luker**, VP Lilly New Ventures and Emerging Technology, **Eli Lilly**

1:1 Partnering (24 hours all week)

16:00 Afternoon Keynote Panel: New Decade, New Challenges – Pharma M&A And Deal-Making

The biopharma industry has been continually, setting and then breaking records across multiple metrics in the last decade; active clinical trials and R&D pipelines are at all time highs, as are drug sales and new regulatory approvals for new treatments. As we enter the 2020s, there has been a noticeable shift by the industry’s biggest players towards restoring operational balance and in some cases a greater focus on internal assets, rather than larger external acquisitions, while maintaining the flexibility for bolt-on acquisitions. And the decade could have hardly gotten off to a worse start with COVID-19 putting a temporary halt to activity for much of H1. How do the biopharma industries biggest deal-makers see the future of pharma M&A and deals? Global heads of Pharma BD & M&A discuss the outlook for 2021 and beyond.

Moderator: **Robbie McLaren**, Partner, **Latham & Watkins**  
**Philippe Lopes-Fernandes**, EVP & CBO, **Ipsen**  
**Aradhana Sarin**, CFO, **Alexion Pharmaceuticals**  
**Elizabeth Mily**, EVP BD, **BMS**  
**Ben Thorner**, SVP and Head MRL Business Development & Licensing, **Merck & Co**

17:00 Virtual Drinks Reception

1:1 Partnering (24 hours all week)



Thursday, February 4 - all times in GMT

09:00	<div>Welcome Address</div> <div>Josh Dance, SVP, LSX</div>
09:10	<div>Presentation And Regulator Q&amp;A: Support For Europe’s SMEs And Innovation</div> <div>Helene Casaert, Regulatory Science and Innovation Task force, SME office, European Medicines Agency Constantinos Ziogas, Head of SME Office, European Medicines Agency</div>
10:00	<div>Panel: “If I Had Known Then What I Know Now” – Best Practices For Entering The US Market</div> <div>Whether it’s patent strategy, working with potential investors or partners, or navigating the regulatory framework, what lessons can be learned from successful market entrants? And what pitfalls can companies avoid as they approach this major milestone in their development? This session will bring a broad range of perspectives from those who have experienced the challenges first-hand – companies that have successfully entered the market and those who have advised or funded companies doing the same. The groups discusses preparing a patent portfolio for US clinical development, approval, and market entry, driving IP opportunities and value based on clinical and regulatory insights and coordinating clinical development and IP portfolio development.</div> <div><div><div>Perspectives from the European and US sides of a company who have entered the US market</div><div>Key success factors from a seasoned entrepreneur</div><div>Investor insight on preparation for entering the US</div></div><div>Moderator: Teresa Lavoie, Principal, Fish &amp; Richardson Darrin Disley, CEO, Mogrify Nanna Lüneborg, Partner, Novo Ventures Jan Mattsson, Chief Scientific Officer and Co-Founder, Albireo Jason Duncan, Chief Legal Officer and General Counsel, Albireo</div></div>

1:1 Partnering (24 hours all week)

11:00	<div>Panel: Female Founders – Encouraging, Developing And Commercialising Talent</div> <div>Statistics of representation on boards, the imbalance of investment into female entrepreneurs and the wider gender imbalance in life sciences and healthcare businesses shows we still have a long way to go. Women’s health is considered by some as a niche, when it is anything but. Too often, lip service can be paid to the cause without effective action, and the importance of business networks, mentorship and thought leadership in tackling the issue of gender cannot be underestimated. Inspiring female founders discuss the challenges they have faced in building their life science and healthcare businesses, raising capital in a male-dominated industry, and what more can and should be done to expedite growth and equality in female entrepreneurship and leadership in life sciences. Importantly, how can the wider industry, and the men within, best play their part and make a true and meaningful difference.</div> <div>Moderator: Angela Tyrell, SVP, Longevity Leaders Sharon Cunningham, Co-Founder and CEO, Shorla Pharma Lea Von Bidder, Co-founder and CEO, Ava Caroline Barelle, Co-Founder and CEO, Elasmogen Valerie Vanhooren, Co-Founder and CEO, ONA Therapeutics Fiona MacLaughlin, Senior Director, Johnson &amp; Johnson Innovation JJDC Inc</div>
12:00	<div>Presentation: Readiness Assessments For Coming To The US - Are You Ready For Prime Time?</div> <div>Any life sciences company will, sooner or later, be looking to enter the largest healthcare healthcare market in the world. Biotechnology is a global business, and any startup and growing biotech should be planning early for their US market entry. But what are the key considerations for none-American companies who are looking to grow, internationalise, build their networks, partners and presence in the US, particularly during this difficult period where travel?</div> <div><div><div>How it is never too early to be ready with integrated development and commercialization strategies</div><div>Critical aspects positioning companies for success</div><div>Making your company more appealing to US and global partners</div></div><div>Matt Cardinal, Principal, Halloran Consulting Group Cornelia Kroeger, Senior Consultant, Halloran Consulting Group</div></div>
13:00	<div>Panel: Why Early? - Optimizing Long-Term Success Through Earlier Synchronization Of Commercial And Clinical Strategy</div> <div>The increasing likelihood of early approval or of going to market alone requires a shift in how companies think about the relationship between commercial and clinical development. Executives who are on the journey to commercialisation discuss how best to shape a successful future through timely synchronization of clinical and commercial strategy.</div> <div><div><div>Defining an ambitious and achievable vision of future value</div><div>Identifying key enablers and potential barriers through early commercial thinking</div><div>Understanding the route-map, milestones, and decision-points for commercialization</div><div>Exploring the rationales for ‘going it alone’ vs ‘deal-making’</div></div><div>Moderator: Carl Engleman, Vice President, Cello Health Consulting Erik van den Berg, CEO, AM-Pharma Denise Scots Knight, CEO, Mereo BioPharma Steven Powell, CEO, eTheRNA</div></div>

1:1 Partnering (24 hours all week)

14:00	<p><b>Presentation: Avoiding CMC Failures Through Phase-Appropriate Clinical Development And Supply Chain Setup</b></p> <p><i>Today's clinical pipelines are at record levels and driven by innovation in approach including use of AI in discovery and ongoing investment in new and more patient-centric therapies. More and more of these programs follow accelerated development and approval pathways. As a result, target timelines for the start of clinical trials are getting shorter and shorter. In this already complex environment, Chemical and Manufacturing Controls should not be the cause for increased risk or delays. This presentation will cover phase-appropriate development approaches, and supply chain solutions, for integrated drug substance and drug product projects that can accelerate program timelines and reduce overall complexity and risk.</i></p> <p><b>Rhony Aufdenblatten</b>, Head of Commercial Development, Combined Offerings Small Molecules Business Unit, <b>Lonza Pharma &amp; Biotech</b></p>
15:00	<p><b>Presentation And Panel: First Launch And Commercialisation 2011-2020 – Spotlight On Rare Diseases And Oncology</b></p> <p><i>It's one small step for pharma, but one giant leap for an emerging biopharma company successfully navigate a successful first launch with the final stage of development being bigger, more expensive, more complex, and with a huge amount at stake. A maturing ecosystem is increasingly empowering companies towards that first launch however, particularly in oncology and rare diseases – what can these trend tell us and what are the main considerations and things to plan early for companies looking to commercialise their first products? After an introductory presentation reviewing novel first launches in 2011-2020 in Europe and the US and an overview on landscape, executives from emerging pharma leaders discuss their current or previous journey and experiences in commercialisation.</i></p> <ul style="list-style-type: none"><li>• Highlighting oncology and rare disease first launches as well as cell and gene therapy and implications of the rise of the sector</li><li>• Key success factors in a first launch</li><li>• Exit valuations after commercialisation compared with partnering up</li></ul> <p>Presenter and moderator: <b>Ben Hohn</b>, Principal - BD, Pipeline and Launch Strategy, <b>ZS Associates</b> <b>Liz Barrett</b>, CEO, <b>Urogen</b> <b>Naseem Amin</b>, CEO, <b>gmp-orphan</b> <b>Kieran Rooney</b>, VP, Strategic Alliances and Licensing, <b>Amryt Pharma</b></p>
16:00	<p><b>Innovation In Regulation; What Developers And Investors Need To Know</b></p> <p><i>Emerging biopharma companies have to incorporate long-term thinking about disease landscape, patient needs, emerging technologies and market conditions to near term interactions with health authorities when very little is known about a new product. We will explore how innovation in regulation – advanced by the sense of urgency of the pandemic, drives early value creating regulatory touch points along the development continuum in high unmet need disorders.</i></p> <p>Moderator: <b>Laurie Smaldone Alsup</b>, CSO/CMO, <b>NDA Group</b> <b>Steffen Thirstrup</b>, Former Chief Medical Officer, <b>Danish Medicines Agency</b> and Director, NDA Regulatory Advisory Board, <b>NDA Group</b> <b>Ed Kaye</b>, CEO, <b>Stoke Therapeutics</b></p>

1:1 Partnering (24 hours all week)

17:00	<p><b>Presentation: Challenges And Technology Solutions For Dual Eligible Populations In The US</b></p> <p><i>In the United States, there are roughly 12 million patients that are dual eligible for both Medicare and Medicaid, and if patients that are intermittently eligible for Medicaid are included this increases to 40% of the 44 million Medicare beneficiaries. About 18 million (30%) of Medicare members live at less than 150% of the Federal Poverty Level, 50% of which spend more than 20% of their annual income (about \$3,500) on health costs. This group have a high risk of chronic health conditions and frequently need long term care and, with high rates of underlying health conditions, they are particularly at risk of COVID-related death. This not only highlights the health disparity of these patients versus non-duals but also fosters an urgency to find effective solutions. There are numerous barriers and difficulties when addressing the healthcare needs of this population and emerging health technologies offer a new set of tools that are not yet being universally applied in the care of dual eligible people.</i></p> <ul style="list-style-type: none"><li>• Characterising the barriers to addressing duals’ health needs</li><li>• The new technologies applicable to dual eligible care</li><li>• Explaining future directions in technological investment to better serve dual eligible people</li></ul> <p><b>Andrey Ostrovsky</b>, Former Chief Medical Officer, US Medicaid Program; Managing Partner, <b>Social Innovation Ventures</b></p>
-------	--

Friday, February 5 - all times in GMT

09:00	1:1 Partnering Continued
-------	--------------------------

1:1 Partnering (24 hours all week)



Day 1 - IPO Bootcamp

Day 2 - Life Science & Digital Health Partnerships

Day 3 - Capital Markets & Investment

Day 4 - Payers, Providers & Reimbursement

Day 5 - 1:1 Partnering

Tuesday, February 2 - all times in GMT

09:00 Welcome Address  
Becky Johnson, Conference Director, LSX

10:00 Panel: How Pharma Is Investing In Healthcare’s Future

*The Biopharma sector has never been more conscious of the disruptive potential of digital health. For several years, industry leaders have taken increasingly proactive approaches to innovation, leveraging investment, partnerships and acquisitions to bolster their digital strategies, to create more personalised patient experiences, and to enhance traditional pharma product lines. Against this backdrop, and that of COVID-19, which has shown as never before the urgency of healthcare transformation, how are the pharma’s investment leaders approaching digital health innovation, and how can innovators work begin to work with pharma? A panel of digital health investment experts from the biopharma sector dive into this essential issue.*

- The bottom line - digital health’s disruptive potential in biopharma
- Partnership vs acquisition: long term strategies when investing in innovation
- How and why COVID-19 has boosted investment levels

Moderator: Lala Gregorek, Analyst, Trinity Delta  
Rana Lonnen, Head of Search and Evaluation, Strategic Capital, Novartis  
Bruce Meadows, Head of Investments, Takeda Digital Ventures  
Lara Koole, Founder and Partner, Philips Ventures

11:00 Panel: Drug Discovery And Development In The Era Of AI And Analytics

*The life science sector has struggled for years with expensive, inefficient drug discovery and high failure rates in drug development. Now, new technologies like artificial intelligence, machine learning, and data analytics promise to revolutionise biopharma R&D with in-silico drug design, sophisticated analysis of highly complex data sets, and an accelerated path through the clinic and to market. But what is the reality on the ground behind the buzz? Just how remote is the R&D model promoted by AI evangelists, and what are the major hurdles that R&D teams and innovators still must overcome if that model is to become reality? A panel of biopharma R&D transformers discuss the potential of artificial intelligence and data-driven technologies to create a new digital R&D paradigm.*

- “Necessity is the mother of invention” – why is AI so valuable to R&D teams?
- How successful has innovation in the R&D space been thus far?
- Commercialising data-driven drug discovery and development technologies

Moderator: Bill Aronson, COO, Artificial Intelligence Research Group  
Jackie Hunter, Board Director, BenevolentAI  
Abraham Heifets, Co-Founder and CEO, Atomwise  
Martin-Immanuel Bittner, Co-Founder and CEO, Arctoris  
Nick Scott-Ram, Managing Director, Discovery Sciences, Sensyne Health

1:1 Partnering (24 hours all week)



12:00

Panel: Will Digital Turbo-Charge Clinical Development?

Clinical trials are expensive, time-consuming, full of logistical inefficiencies and reliant on high-quality data - they are therefore a natural beneficiary of digital technology: higher quality, more standardised data; better patient adherence rates; increased recruitment and lower drop-out rates. And in light of the coronavirus and resultant social distancing measures, meaningful innovation is now essential. A panel of clinical trial innovators discuss the drivers of digitalisation, and the challenges holding back clinical trial transformation.

- Understanding the limitations of existing clinical trial models
- What are the key factors holding back new clinical trial innovation and digitalisation?

Moderator: Dan Kendall, Managing Director, Mission Based Media

Laurent Schockmel, CEO, Antidote.me

Charles K. Fisher, Founder and CEO, Unlearn.AI

Katherine Li, CEO, BrainBase Line

13:00

Panel: Unlocking The Potential Of The Genomics Revolution

The possibilities opened up by improved knowledge of the human genome are almost limitless. Paired with AI and gene editing techniques, genomic data will facilitate superior treatment of genetic disease, while expanded pharmacogenetic research will facilitate ever more personalised healthcare interventions. Outside of the clinic and the world of research, genomic information will also work alongside connected digital devices and monitoring systems to put self-management and prevention at the core of healthcare. But all this depends on genomic literacy among clinical staff and researchers; likewise, improvements to clinical care are dependent upon continued data-driven genomic research, and therefore upon patient support. A panel of genomic innovators and stakeholders explain the potential of genomics in healthcare and the life sciences, and the challenges which the ecosystem still must overcome in order to capitalise.

- How can our developing understanding of the genome facilitate better and more personalised healthcare?
- Getting patients onboard and clinical staff up to date with genomics research
- Next steps – with the capital flowing in, what’s still missing?

Moderator: Joanne Hackett, General Partner, IZY Capital

Alex Aravanis, Chief Technology Officer, Illumina, Co-Founder, Grail

Lisa Alderson, CEO, Genome Medical

Dennis Grishin, Co-Founder, Nebula Genomics

1:1 Partnering (24 hours all week)

14:00

Panel: Digital Therapeutics – Creating And Commercialising Clinically-Validated Innovation

Digital therapeutics have attracted billions of dollars in VC investment and high-profile collaboration deals with big pharma; despite growth pains and questions around commercial formulas, reimbursement pathways, and adoption and retention, the DTx market has demonstrated a very real value proposition and succeeded in engaging key stakeholders across healthcare and life sciences. A panel of digital therapeutics leaders discuss the challenges facing the market, its emergent commercialisation model, and key learnings from recent collaboration efforts.

- Key success factors for development and commercialisation of digital therapeutics
- Perspectives on pharma-DTx partnerships
- Driving uptake by payers, providers and patients

Moderator: Dan Kendall, Managing Director, Mission Based Media

Jesaja Brinkmann, CEO, Cara Care

Megan Coder, Executive Director, Digital Therapeutics Alliance

Zach Henderson, CCO, Glooko

Lauren Li, Head of Digital Health, Ipsen

15:00

Panel: Optimising Real-World Evidence And Real-World Data

An explosion of real-world evidence and data has introduced a new dynamic to pharma business models: RWE and RWD can complement clinical data, accelerate R&D, and drive major regulatory, reimbursement and pricing decision – and may prove invaluable in the fight against COVID-19. Expansion of its use, however, requires co-ordinated action across the healthcare value-chain, as well as thorough consideration of the behavioural, social, genomic and environmental factors contributing to health outcomes. A panel of innovators and pharma executives explore strategies to access and optimise RWD and RWD and the impact they will have for healthcare and life sciences.

- RWE and RWD use-cases in and out of the clinical setting
- Tracking and understanding behavioural health factors
- How can industry players collaborate to share and leverage real world evidence and data?

Moderator: Rachel Ford Hutman, Founder and CEO, Ford Hutman Media

Adrian Cassidy, Global Head of Real-World Evidence, Novartis

Carolyn Magill, CEO, Aetion

Lori Evans Bernstein, President and Chief Operating Officer, HealthReveal

Vindell Washington, Chief Clinical Officer, Verily Life Sciences

Mikki Nasch, Co-Founder and VP Business Development, Evidation Health

1:1 Partnering (24 hours all week)

16:00

Keynote Panel: Turning Pharma Into Digital-First Organisations

*In response to the rising tide of digital innovation, big pharma is reassessing the fundamentals of its business model, revisiting its core USPs, and initiating deep, cross-sector collaborations to create outcome-based, patient-focused commercial strategies. AI and data-driven technologies are fast revolutionising pharma's traditional R&D work, and the patient experience and perspective are becoming a crucial element of transformation strategy. A panel of pharma digital leaders discuss and debate the potential of digital to reconnect with patients, improve R&D efficiency and enable a paradigm shift in the commercial model of the life sciences sector.*

- The big picture – why is pharma prioritising digital transformation?
- In-house innovation vs partnerships
- How can big pharma marry it's traditional business models with the patient-centricity necessary to become 'digital-first'

Moderator: Catherine Longworth, Web Editor, pharmaphorum

Josh Raysman, Vice President Digital Innovation Lab, Pfizer

David Christie, Head of Digital Strategy Implementation, CSL Behring

Rajni Aneja, Head of Digital Transformation and Strategy, Sanofi

17:45

Virtual Drinks Reception

Wednesday, February 3 - all times in GMT

09:00

Welcome Address

Becky Johnson, Conference Director, LSX

1:1 Partnering (24 hours all week)

10:00

Keynote Panel: Yielding Dividends From Europe's Digital Health Scene

*While technology is inexorably converging with healthcare all around the world, the US market still grabs the lion's share of the headlines. But the European healthtech start-up scene is booming too, with European innovation already materially creating cost-savings, improving patient outcomes, and in many cases approaching true return on investment. From digital therapeutics, clinical tools and R&D transformation, to telehealth and connected consumer health products, European innovation is gaining massive traction and attracting major investments. Forward-looking European digital health investors discuss the segments of the digital health ecosystem with the most promise, and where to look for the next big investment opportunity.*

- The challenges of commercialising digital health in the European context
- Advantages of innovating in European health systems
- European investment trends in the healthtech – will the boom last?

Moderator: David Germonpre, Investment Partner, MTIP

Christian Weiß, Managing Partner, Heal Capital

Katrin Geyskens, Partner, Capricorn Partners

Michael Niddam, Co-Founder, Kamet Ventures

Inga Deakin, Principal, Draper Esprit

Heather Roxborough, Partner, Optum Ventures

11:00

Keynote Panel: The BD Outlook - Are Medtech's Movers And Shakers Ready To Resume?

*In what has been anything a normal year, the medtech sector has proven relatively robust despite a predictably quiet H1; deal-flow is hopefully now set to return to healthy levels, with many major deals in the works and medtech commercial leaders eyeing further expansions and consolidations. But what impact has COVID-19 had on the M&A and BD trends? In addition to revealing vulnerabilities in many supply chains and parts of the sector, where has the pandemic created or highlighted opportunities that medtech innovators and commercial leaders can grasp? A panel of the medtech business development leaders discuss all this, and more.*

- Moving past the COVID-19 BD dip
- Catching up with commercial leader pipelines
- M&A – what segments is big medtech targeting?

Moderator: Elizabeth Cairns, Medtech Reporter, Vantage

Charity Kufaas, VP BD and Strategy, Medtronic

Xavier Bertrand, VP Healthcare Services and Alliances, Boston Scientific

Finn Haley, VP Corporate Development, Edwards Lifesciences

Rupert Winckler, Head of BD EMEA, Olympus

1:1 Partnering (24 hours all week)



12:00	<div><div>Case Study: Making Digital Therapeutics Work: 10 Principles To Drive Patient Engagement</div><div><p><i>We have a serious adherence problem. Each year, medication non-adherence contributes to 125,000 preventable deaths, 25% of all hospitalizations and 50% of treatment failures in the US alone; enter DTx (digital therapeutics) products. Digital therapeutics are evidence-based digital therapeutic interventions to prevent, manage, or treat a medical disorder or disease. They've already proven effective in improving adherence in a wide range of health conditions, including diabetes management, MSK physiotherapy and asthma.</i></p><p><i>Listen as Christopher explores the Digital Therapeutics product landscape to uncover the key design principles being commonly used to drive patient engagement and improve adherence to treatment plans. Using real life examples, he will unpack the various types of engagement tactics being commonly used, such as quantifying progress, community, and certified guidance, and he will explain how new technologies such as Voice AI and Digital Biomarkers are reducing the barriers of data entry by making active tracking more effective.</i></p><div>Chris Scales, Director of Strategy and Insight, Star</div></div></div>
13:00	<div><div>Panel: The Evolution Of The Traditional Medtech Investor; What Attracts Capital In 2021?</div><div><p><i>Traditional medtech holds huge promise for the investment community, but is often regarded as a challenging prospect, when compared to biotech or the booming digital health sector. But with a new generation of connected medical devices and diagnostics, leveraging AI, analytics, and big data, often in conjunction with pure digital health, medtech investors are fast developing new approaches and focuses, and diversifying their portfolios. A panel of innovation-minded medtech investors discuss and debate the role of the medical technology in today's healthcare ecosystem and how early stage medtech companies can continue to appeal to the investment community.</i></p><div><div><div>• How have medtech investment strategies changed with the rise of digital?</div><div>• What early stage 'traditional' medtech companies must do to refine their pitch</div><div>• Evidence - commercial traction - investment? Setting out for success in medtech</div></div><div><div>Moderator: Tina Tan, Executive Editor, FirstWord Healthtech</div><div>Tamir Meiri, Senior Manager, Venture Investments, Johnson &amp; Johnson Innovation - JJDC, Inc.</div><div>Sascha Alilovic, Managing Partner, SHS Capital</div><div>Rainer Strohmenger, Managing Partner, Wellington Partners</div><div>Daniel O'Mahony, Partner, Seroba Life Sciences</div><div>Fernando Pacheco, Investment Director, Endeavour Vision</div></div></div></div></div>

1:1 Partnering (24 hours all week)

14:00	<div><div>Panel: Capital And Dealfow In China's Booming Medtech Market</div><div><p><i>As the world's second largest medtech market, China has become massive strategic priority for European and US Medtech companies, a fact borne out by a slew of recent investment and partnerships. But closing a cross-border investment or licencing deal in China is no simple matter, requiring a deep understanding of its commercial and consumer landscape, as well as the commercial models and strategies of its major medtech players. A panel of executives hailing from and entering into China's medical technology market discuss and debate the best strategies to develop and close successful deals and investments in the region.</i></p><div><div>Moderator: Ari Silverman, Partner, Mavie Technologies</div><div>Jay Yin, Partner, Bioventure</div><div>Daniel Wang, Managing Partner, TUSPARK Capital Management</div><div>Peggy Wang, Chairman, Mitrassist</div></div></div></div>
15:00	<div><div>Panel: Is Your Healthtech Innovation Investor-Ready?</div><div><p><i>Healthtech fundraising saw a massive boost throughout 2020, accelerated by lockdown and quarantining measures. But there are numerous factors a healthtech company must consider before raising a successful Series A: clinical evidence and proof of concept are not always sufficient, with investors often expecting commercial traction, regulatory approvals, and advanced reimbursement and IP planning, before investing. What have the key success factors been in for recent healthtech fundraises, and what lessons can future waves of healthtech companies seeking financial backing learn from them? A panel of executives with recent fundraising experience discuss.</i></p><div><div><div>• What do investors need to see in healthtech innovation before parting with capital?</div><div>• Other than evidence of efficacy, what do healthtech companies need to do to prove that they are ready for the next commercial steps?</div></div><div><div>Moderator: Peter Finnie, Partner, Potter Clarkson</div><div>Clara Campàs, Co-Founder and Managing Partner, Asabys Partners</div><div>Thom Rasche, Managing Partner, Earlybird Capital</div><div>Hakim Yadi, CEO, Closed Loop Medicine</div><div>Tryggvi Thorgeirsson, CEO and Co-Founder, SidekickHealth</div></div></div></div></div>
16:00	<div><div>Interview: Innovation And The Future Of Chronic Disease Management</div><div><div>Moderator: Tina Tan, Executive Editor, FirstWord Healthtech</div><div>Glen Tullman, Founder, Livongo</div></div></div>

1:1 Partnering (24 hours all week)

17:00    **Keynote Investment Panel: The New 2021 Digital Health Investment Landscape**

*As innovation redefines healthcare and life sciences as never before, investment continues to play a crucial role in driving transformation – so where do digital health’s leading investors see opportunity? Has the digital health investment cycle reached and passed its peak? What market challenges continue to impede commercialisation and ROI of digital health innovation? And of course, what will be the impact of COVID-19? A panel of leading investors discuss and debate the developing digital health investment landscape, emergent investment and exit strategies, and future capital and deal-flow.*

**Moderator: Rachel Ford Hutman**, Founder and CEO, **Ford Hutman Media**  
**Jessica Federer**, Partner, **Boston Millennia Partners**  
**Michael Greeley**, General Partner, **Flare Capital**  
**Steve Tolle**, Partner, **HLM Ventures**  
**Robert Garber**, Partner, **7wireventures**  
**Andrea Jackson**, Director, **Northpond Ventures**

Thursday, February 4 - all times in GMT

09:00    **Welcome Address**

**Becky Johnson**, Conference Director, **LSX**

10:00    **Morning Keynote Panel: Driving Digital Health Adoption Across Europe**

*Healthcare systems are busy rolling out a plethora of digital tools and applications, across health IT, telehealth and m-health to blockchain, advanced analytics and AI, to be implemented throughout primary care and speciality care, the front line and the back office. But there is still a way to go until adoption of digital health is fully aligned with clinician workflows, payment and reimbursement mechanisms, and the needs and preferences of patients. A panel of government and healthcare leaders discuss the potential and challenge of integrating digital health innovation into healthcare systems, where there is value to be delivered and where the major stumbling blocks will be along the way.*

**Moderator: Tobias Silberzahn**, Partner, **McKinsey**  
**Daniel Forslund**, Chairman Innovation & Development Committee, **Region Stockholm**  
**Brian O’Connor**, Chair, **European Connected Health Alliance**  
**Päivi Sillanaukee**, Ambassador for Health and Wellbeing, **Ministry for Foreign Affairs of Finland**  
**Gottfried Ludewig**, Head of Department for the Digitisation of Public Health, **Federal Ministry of Health, Germany**

1:1 Partnering (24 hours all week)

11:00    **Fireside Chat: The US Payer Perspective On Telemedicine**

*Digital is becoming a key strategy by which the US insurance and healthcare giants can defend market share against disruptive tech companies and payer start-ups, as well as to out-strip other incumbents and capture new ground. Digital is moreover a crucial consumer engagement tool, creating frictionless enrolment processes, minimise time-consuming administrative tasks, better predicting member needs and moving the needle toward value-based models. We talk to Kristi Henderson about how she, and Optum, are approaching digitisation and the move to telemedicine, as well as how she sees the future of digital health and care.*

**Kristi Henderson**, SVP Innovation Telehealth, **Optum**

12:00    **Fireside Chat: Reimagining Healthcare Delivery And Access On A Global Scale**

- What are the key challenges of healthcare access and how can digital help?
- How has the Novartis Foundation been able to successfully introduce scalable innovation to patients in low-income communities?

**Ann Aerts**, Head Novartis Foundation, **Novartis**

13:00    **Panel: The Role Of Digital In The Transition To Value-Based Care**

*In a bid to control spiralling healthcare costs and deliver superior patient outcomes that justify payer reimbursements, health systems are increasingly moving toward value-based models, which many believe will be a lynchpin in the development of preventative care. But such a transition will require collaboration across the value-chain, closer patient engagement, and new approach to evidence and R&D. A panel of healthcare stakeholders and innovators dive into the value-based care and value-based reimbursement discussion, the factors driving its development, and the challenges still impeding its realisation.*

**Moderator: Gil Rabbie**, Digital Solutions and Capability Development Leader, **Boston Scientific**  
**Mark Davies**, Chief Medical Officer, **EMEA, IBM Watson Health**  
**Corbin Petro**, CEO, **Eleanor Health**  
**Tim Gronniger**, CEO, **Caravan Health**  
**Niamh Mckenna**, CIO, **NHS Resolution**

14:00    **Panel: In Dialogue With Healthcare’s New Entrants**

*While collaboration and competition between start-ups and traditional healthcare stakeholders is driving major disruption, innovation is increasingly coming from total outsiders to healthcare: consumer brands with large and well-engaged customer and user bases; social media giants with enormous data resources and sophisticated digital platforms; corporations looking to leverage existing service lines to reimagine healthcare management and access. A panel of new entrants into the healthcare space discuss the key USPs that outsiders can bring to the sector, and what the future of healthcare will look like as it evolves beyond its traditional ecosystem.*

**Moderator: John Hodgson**, Independent Consultant  
**Jennifer Esposito**, VP Health, **Magic Leap**  
**Lisa Bookwalter**, Director, Twitter Client Solutions, **Health, Twitter**  
**Tom Waller**, SVP Advanced Innovation, **Iululemon**

1:1 Partnering (24 hours all week)



15:00	<b>Fireside Chat: The German Example – Accelerating Adoption Of Healthtech Innovation</b>  Henrik Matthies, Managing Director, Health Innovation Hub, Federal Ministry of Health, Germany
16:00	<b>Panel: Next-Generation Hospitalisation; The Patient Care Experience Of The Future</b>  <i>Hospital transformation has become a top priority for national and regional health systems, as a range of innovations from connected diagnostics, AI-driven data analysis and triaging, to voice technology and remote care in the context of COVID-19, become ever more prevalent and impactful. While healthcare, and especially hospital care, remains notoriously risk averse, digital health is booming across the world. For all the challenges associated with adoption of healthtech in the clinical setting, clinicians themselves are clear: innovation is needed to support access to patient data, to create more efficient workflows and reduce burnout. A panel of hospital and healthcare executives discuss emerging hospital transformation strategies, their approaches to the healthtech start-up ecosystem, and the critical success factors for successful adoption and integration of digital health.</i>  Moderator: Sarah Elizabeth Richards, Health and Science Journalist, WIRED Karen Murphy, Chief Innovation Officer, Geisinger Adam Landman, Chief Information and Digital Officer, Brigham and Women’s Hospital Neil Sebire, Chief Research Information Officer (CRIO), Great Ormond Street Hospital
17:00	<b>Panel: Re-Designing And Re-Defining Diagnostics With AI And Data</b>  <i>The diagnostics sector has seen a burst of data and artificial intelligence-driven innovation across all its verticals. Adoption of AI, machine learning and deep learning in diagnostics will drive major cost- and time-savings for providers, speed up diagnoses, and ultimately save patient lives. Markets have been buoyed both by regulatory approvals and by research indicating that AI may have reached a level of diagnostic accuracy comparable to that of a human clinician – the sector is now set to see massive growth over the coming years. But what challenges remain for the innovators bringing AI to the sector and for would-be adopters? A panel of diagnostic, imaging and pathology innovators discuss crucial success factors for bringing AI-enabled diagnostics into healthcare systems, from R&amp;D, to regulatory approval, to uptake by healthcare professionals.</i>  Moderator: Adam Dakin, Managing Director, Dreamit Ventures Thomas Hummel, Head of Innovation and Strategy, Siemens Healthineers Wim Van Hecke, CEO, icometrix Liam Kaufman, CEO, Winterlight Labs John Bertrand, CEO, Digital Diagnostics
18:00	<b>Closing Keynote: Digital Knows No Boundaries</b>  <i>Digital technologies are reshaping industries around the world. Consumers are expecting hyper-personalized experiences, and COVID-19 has accelerated the need to create and embrace new models of care. We have the opportunity to utilise the power of data, platforms, and AI, in tandem with research and partnerships, to create a healthcare ecosystem that enables an exponentially greater level of information sharing. Join Rajeev Ronanki to learn how Anthem’s ecosystem and partnerships drive an interoperable and personalised approach to healthcare.</i>  Rajeev Ronanki, SVP and Chief Digital Officer, Anthem

1:1 Partnering (24 hours all week)

Friday, February 5 - all times in GMT	
09:00	1:1 Partnering Continued

1:1 Partnering (24 hours all week)



Day 1 - IPO Bootcamp

Day 2 - Design, Development & Digitalisation

Day 3 - Capital Markets & Investment

Day 4 - Market Access & Commercialisation Strategy

Day 5 - 1:1 Partnering

Tuesday, February 2 - all times in GMT

09:00	<b>Welcome Address</b>  Angela Tyrrell, SVP, LSX
10:00	<b>Keynote Commercial Leader Panel: Brave New World – Europe’s Post Covid-19 Medical Technology Landscape</b>  <i>Europe is home to some of the world’s most exciting medtech technologies and innovative healthcare systems - but it has traditionally been deemed less appealing than the more capital rich US market, given its smaller venture rounds, lower M&amp;A levels, and, in recent years, the regulatory upheaval of MDR. But how has the arrival of the ubiquitously disruptive COVID-19 pandemic impacted European medtech? With the importance of medical devices, diagnostics and equipment, and the work of both medtech commercial leaders and innovators thrust into the public consciousness as never before, is there a silver lining for the medtech sector? A panel of EMEA medtech executives discuss all this and more.</i>  Moderator: Dan Kendall, Managing Director, Mission Based Media Didier Deltort, President EMEA, Zimmer Biomet Rob Ten Hoedt, President EMEA, Medtronic
12:00	<b>Keynote Panel: Patient-Centric Approaches In Medtech</b>  <i>The surge in innovative medical technologies and devices in recent years has elevated patients to true stakeholders in the medtech ecosystem. It is now imperative for device manufacturers, diagnostic companies, and health systems to design their products with the patient experience in mind: comfort, convenience and connectivity all now constituting essential traits of a successful medical technology. So how are medtech manufacturers and innovators ensuring that patient-centricity is truly built into their products? A panel of medtech execs reveal their strategies from early stage in design to commercialisation.</i>  Moderator: Lala Gregorek, Healthcare Analyst, Trinity Delta John Milad, CEO, Quanta Marc Julien, Co-CEO, Diabeloop Ian Crosbie, CEO, Sequana Medical

1:1 Partnering (24 hours all week)



13:00	<p><b>Panel: Delivering Scale And Value Through Collaboration And Partnerships</b></p> <p><i>A well-matched medtech partnership can bring deliver immense value to the constitutive parties, becoming more than the sum of its parts by expanding client pools and critical data assets, and creating more multi-dimensional market access and growth strategies. But whether the partnership is between an academic institution and a start-up, a start-up and a commercial leader, a commercial leader and a tech player, or any other combination, certain challenges have make-or-break potential – timing, IP, commercial objectives and much more. A panel of medtech executives with a history of shared collaborations share tips, warnings, and war stories.</i></p> <p><b>Moderator: Adam Dakin, Managing Director, Dreamit ventures</b> <b>Sergio Levi, VP and Head of Strategic Alliances, Philips</b> <b>Seamus Browne, Head of Industry Partnerships, Royal College of Surgeons</b> <b>Xavier Bertrand, VP Healthcare Services and Alliances, Boston Scientific</b></p>
14:00	<p><b>Presentation: The Critical Role Of Preclinical Science In The Advancement Of Healthcare: Lessons Learned From Innovations In Vascular Intervention</b></p> <p><i>Innovation drives the advancement of health care. Far from a random moment of inspiration, successful innovation follows a disciplined development path. Before new technologies can reach the clinic, careful planning to define and complete the right preclinical studies with the right models is vital to satisfy key stakeholders and propel the program to the next stage. Vascular Intervention is a rapidly growing segment of cardiovascular medicine, with myriad devices including arterial and venous stents and stent grafts; angioplasty balloons; devices for drug delivery, embolization, thrombectomy and vascular closure; vascular filters, bioresorbable scaffolds, surgical sealants and others. These devices are growing in sophistication, and so are the studies required to evaluate their safety and effectiveness.</i></p> <p><i>In this session, experts from IMMR, market leaders in the design and conduct of MedTech, Biopharma and Biotech preclinical studies in large models, explore the critical role of preclinical science in health care innovation, with emphasis on the increasingly important vascular intervention space.</i></p> <ul style="list-style-type: none"><li>• Why preclinical science is an essential component of innovation in health care</li><li>• The phases of preclinical research and core value creation at each phase</li><li>• Approaches and pathologic models for vascular interventional studies</li></ul> <p><b>Luc Behr, DVM, PhD, Co-Founder and Scientific Director, IMMR</b></p>
15:00	<p><b>Panel: The Role Of Product Design In Successful Medtech Commercialisation</b></p> <p><i>Design has become a priority at the highest levels of the medtech sector in recent years, especially as connectivity, patient-centricity, and digitalisation exert greater and greater influence on the success not just of devices, but also diagnostics, implantables, surgical equipment and much more. By taking a forward-looking approach to medtech design, innovators can ensure not only regulatory and compliance successes, but greater uptake among payers, providers and patients too. So, what key considerations should medtech entrepreneurs and commercial leaders prioritise in the early stages and how do these translate to success in the long run?</i></p> <p><b>Moderator: Catherine Longworth, Web Editor, pharmaphorum</b> <b>Chas Taylor, Co-Founder MedNova, Novate Medical, former CEO, Veryan Medical</b> <b>Steve Swinson, Chairman, Tibbiyah Holdings, Comphya, Former Chairman Acteon, Vexim, Bone Therapeutics</b> <b>Fredrik Strömberg, Senior Director Northern Europe, Nobel Biocare</b> <b>Claire Woodthorpe, COO and VP Europe, Lightpoint Medical</b></p>

1:1 Partnering (24 hours all week)

16:00	<p><b>Presentation: Capturing The Value Of Digital Innovation In Medtech</b></p> <p><i>Digital technologies have long held the promise of supporting seamless care across the health continuum by reducing care variation, shifting care to post-acute and home settings, and improving chronic disease management. The end goal is value-based, consumer-centric care models that help lower costs and alleviate industry budget pressure. However, this promise has never been fully realised due to buyer ambiguity in how to assess the value of digital products, too many disparate solutions without a comparative framework and a lack of defined commercial models. The COVID-19 pandemic broke down many of the barriers to digital health adoption by creating an immediate need for a replacement to the traditional in-person visit and easing regulatory and reimbursement complications. Providers across the board adopted a range of technologies overnight, from telehealth and remote monitoring to patient engagement solutions.</i></p> <p><i>Medtech organisations now have an opportunity to extend momentum post-pandemic, permanently redefining the default care models of the future. To cement digital solutions as a core element for future growth, medtech companies need targeted competitive strategies and a willingness to flex business models beyond traditional limitations.</i></p> <p><b>Sotiris Rompas, Senior Director, Huron</b></p>
17:00	<p><b>Fireside Chat: In The Trenches Of AI Commercialisation</b></p> <p><b>John Bertrand, CEO, Digital Diagnostics</b></p>
17:45	<p><b>Virtual Drinks Reception</b></p>
<p><b>Wednesday, February 3 - all times in GMT</b></p>	
09:00	<p><b>Welcome Address</b></p> <p><b>Becky Johnson, Conference Director, LSX</b></p>

1:1 Partnering (24 hours all week)

10:00    Keynote Panel: Yielding Dividends From Europe’s Digital Health Scene

*While technology is inexorably converging with healthcare all around the world, the US market still grabs the lion’s share of the headlines. But the European healthtech start-up scene is booming too, with European innovation already materially creating cost-savings, improving patient outcomes, and in many cases approaching true return on investment. From digital therapeutics, clinical tools and R&D transformation, to telehealth and connected consumer health products, European innovation is gaining massive traction and attracting major investments. Forward-looking European digital health investors discuss the segments of the digital health ecosystem with the most promise, and where to look for the next big investment opportunity.*

**Moderator: David Germonpre**, Investment Partner, MTIP  
**Christian Weiß**, Managing Partner, Heal Capital  
**Katrin Geyskens**, Partner, Capricorn Partners  
**Michael Niddam**, Co-Founder, Kamet Ventures  
**Inga Deakin**, Principal, Draper Esprit  
**Heather Roxborough**, Partner, Optum Ventures

11:00    Keynote Panel: The BD Outlook - Are Medtech’s Movers And Shakers Ready To Resume?

*In what has been anything a normal year, the medtech sector has proven relatively robust despite a predictably quiet H1; deal-flow is hopefully now set to return to healthy levels, with many major deals in the works and medtech commercial leaders eyeing further expansions and consolidations. But what impact has COVID-19 had on the M&A and BD trends? In addition to revealing vulnerabilities in many supply chains and parts of the sector, where has the pandemic created or highlighted opportunities that medtech innovators and commercial leaders can grasp? A panel of the medtech business development leaders discuss all this, and more.*

**Moderator: Elizabeth Cairns**, Medtech Reporter, Vantage  
**Charity Kufaas**, VP BD and Strategy, Medtronic  
**Xavier Bertrand**, VP Healthcare Services and Alliances, Boston Scientific  
**Finn Haley**, VP Corporate Development, Edwards Lifesciences  
**Rupert Winckler**, Head of BD EMEA, Olympus

12:00    Case Study: Making Digital Therapeutics Work: 10 Principles To Drive Patient Engagement

*We have a serious adherence problem. Each year, medication non-adherence contributes to 125,000 preventable deaths, 25% of all hospitalizations and 50% of treatment failures in the US alone; enter DTx (digital therapeutics) products. Digital therapeutics are evidence-based digital therapeutic interventions to prevent, manage, or treat a medical disorder or disease. They’ve already proven effective in improving adherence in a wide range of health conditions, including diabetes management, MSK physiotherapy and asthma.*

*Listen as Christopher explores the Digital Therapeutics product landscape to uncover the key design principles being commonly used to drive patient engagement and improve adherence to treatment plans. Using real life examples, he will unpack the various types of engagement tactics being commonly used, such as quantifying progress, community, and certified guidance, and he will explain how new technologies such as Voice AI and Digital Biomarkers are reducing the barriers of data entry by making active tracking more effective.*

**Chris Scales**, Director of Strategy and Insight, Star

1:1 Partnering (24 hours all week)

13:00    Panel: The Evolution Of The Traditional Medtech Investor; What Attracts Capital In 2021?

*Traditional medtech holds huge promise for the investment community, but is often regarded as a challenging prospect, when compared to biotech or the booming digital health sector. But with a new generation of connected medical devices and diagnostics, leveraging AI, analytics, and big data, often in conjunction with pure digital health, medtech investors are fast developing new approaches and focuses, and diversifying their portfolios. A panel of innovation-minded medtech investors discuss and debate the role of the medical technology in today’s healthcare ecosystem and how early stage medtech companies can continue to appeal to the investment community.*

**Moderator: Tina Tan**, Executive Editor, FirstWord Healthtech  
**Tamir Meiri**, Senior Manager, Venture Investments, Johnson & Johnson Innovation - JJDC, Inc.  
**Sascha Alilovic**, Managing Partner, SHS Capital  
**Rainer Strohmenger**, Managing Partner, Wellington Partners  
**Daniel O’Mahony**, Partner, Seroa Life Sciences  
**Fernando Pacheco**, Investment Director, Endeavour Vision

14:00    Panel: Capital And Dealfflow In China’s Booming Medtech Market

*As the world’s second largest medtech market, China has become massive strategic priority for European and US Medtech companies, a fact borne out by a slew of recent investment and partnerships. But closing a cross-border investment or licencing deal in China is no simple matter, requiring a deep understanding of its commercial and consumer landscape, as well as the commercial models and strategies of its major medtech players. A panel of executives hailing from and entering into China’s medical technology market discuss and debate the best strategies to develop and close successful deals and investments in the region.*

**Moderator: Ari Silverman**, Partner, Mavie Technologies  
**Jay Yin**, Partner, Bioventure  
**Daniel Wang**, Managing Partner, TUSPARK Capital Management  
**Peggy Wang**, Chairman, Mitrassist

15:00    Panel: Is Your Healthtech Innovation Investor-Ready?

*Healthtech fundraising saw a massive boost throughout 2020, accelerated by lockdown and quarantining measures. But there are numerous factors a healthtech company must consider before raising a successful Series A: clinical evidence and proof of concept are not always sufficient, with investors often expecting commercial traction, regulatory approvals, and advanced reimbursement and IP planning, before investing. What have the key success factors been in for recent healthtech fundraises, and what lessons can future waves of healthtech companies seeking financial backing learn from them? A panel of executives with recent fundraising experience discuss.*

**Moderator: Peter Finnie**, Partner, Potter Clarkson  
**Clara Campàs**, Co-Founder and Managing Partner, Asabys Partners  
**Thom Rasche**, Managing Partner, Earlybird Capital  
**Hakim Yadi**, CEO, Closed Loop Medicine  
**Tryggvi Thorgeirsson**, CEO and Co-Founder, SidekickHealth

1:1 Partnering (24 hours all week)



16:00 Interview: Innovation And The Future Of Chronic Disease Management

Livongo has long been making headlines as a leader in the digital health innovation, with its public market debut in July 2019, raising \$350m, followed by an \$18.5 billion merger with Teladoc last year. Glen Tullman, Founder and former Executive Chairman and CEO of the company, tells the story of Livongo's rise and shares his thoughts on the future of digital health.

- What sparked the idea for Livongo, its mission, what were the starting blocks for the company's growth?
- Lessons learnt during Livongo's growth trajectory and the key drivers that enabled Livongo to gain real traction
- What challenges did the company encounter and how were they overcome?
- How do you get stakeholders to understand the value of tech-enabled chronic care management?
- Where are the opportunities for true innovation in digital health and chronic care management

Moderator: Tina Tan, Executive Editor, FirstWord Healthtech  
Glen Tullman, Founder, Livongo

17:00 Keynote Investment Panel: The New 2021 Digital Health Investment Landscape

As innovation redefines healthcare and life sciences as never before, investment continues to play a crucial role in driving transformation – so where do digital health's leading investors see opportunity? Has the digital health investment cycle reached and passed its peak? What market challenges continue to impede commercialisation and ROI of digital health innovation? And of course, what will be the impact of COVID-19? A panel of leading investors discuss and debate the developing digital health investment landscape, emergent investment and exit strategies, and future capital and deal-flow.

Moderator: Rachel Ford Hutman, Founder and CEO, Ford Hutman Media  
Jessica Federer, Partner, Boston Millennia Partners  
Michael Greeley, General Partner, Flare Capital  
Steve Tolle, Partner, HLM Ventures  
Robert Garber, Partner, 7wireventures  
Andrea Jackson, Director, Northpond Ventures

Thursday, February 4 - all times in GMT

09:00 Welcome Address

Angela Tyrrell, SVP, LSX

1:1 Partnering (24 hours all week)

10:00 Panel: The Key To Commercialising Innovative Medical Technologies

The rise of innovation in the medtech sector is producing a new generation of connected, data-driven devices, diagnostics, implantables and other technologies capable of delivering superior outcomes faster and with greater cost-effectiveness. But full commercialisation remains challenging, with reimbursement, provider uptake, patient-retention, and compliance all putting pressure on innovators. A panel of medtech CEOs discuss their paths and the lessons learned.

Moderator: Andy Smith, Analyst, Equity Development  
Lea Von Bidder, CEO, Ava  
Amir Zur, Head of Digital Health Products, Teva  
David Braun, Head of Connected Health and Medical Devices, Merck Group

12:00 Presentation: Something In The Way: The Compliance Outlook After Covid-19

Before the COVID-19 pandemic stole the show, the upcoming Medical Device Regulation and In Vitro Diagnostic Regulation were causing much concern in Europe's markets, with timelines putting pressure on many companies and fears that an insufficient number of notified bodies would be designated by the necessary juncture. And while the disruption caused by the pandemic has pushed the MDR deadline back, it has also introduced many fresh challenges which the sector must be ready to confront.

Tina Amini, Medical Device Division Director, NDA Group

14:00 Presentation: How To Create And Scale A True Quality Culture At Your Medical Device Company

The word "quality" can mean different things to different people. Some view quality as simply meeting compliance requirements, while others look at quality as improving the life of a patient who uses their device. For over a century, the most prominent view of medical device quality has been focused on compliance, but in 2021, leading-edge companies are more interested in using true quality as a strategic advantage to hit core business goals. Before they can achieve these organizational outcomes, however, they have to focus on adopting a mindset of true quality. In this presentation, Jon Speer, Founder of Greenlight Guru, will outline the key components of a culture of true quality and give you the action steps you need to take to implement this cultural shift within your organization. Gain insights to help you understand the underlying value of quality and how it can give your company a competitive advantage. Learn about efficient solutions that exist and how to implement them. In doing so, you can significantly improve internal operations, team efficiencies, and above all else, the production of true quality medical devices.

- Learn what it means to have true quality culture and why it matters
- The competitive advantages of adopting a company mindset that reinforces a true quality culture
- Tips on how to create a quality culture within your own organisation
- Understand how this culture can impact your specific company and your medical devices

Jon Speer, Founder, Greenlight Guru

1:1 Partnering (24 hours all week)

15:00

**Keynote Presentation: Bringing Innovative Medical Technologies To Patients**

*We talk to the Director of the Center for Devices and Radiological Health at the US Food and Drug Administration about the challenges of bringing software-based medtech innovation, or software as a medical device (SaMD), to patients and how the FDA has been adapting to the changing environment and constraints during the pandemic.*

- The future of health tech and medtech innovation and safety
- Being more than novel and new - delivering value to patients and consumers
- Regulation and continual modification - managing patient safety and cybersecurity
- Lessons learned from COVID - regulatory flexibility and engagement

**Jeffrey Shuren, Director, CDRH, FDA**

16:00

**Presentation: Evidence Generation For Optimal Market Adoption**

*In contrast to the safety and efficacy data requirements by FDA, to establish market adoption, payers and provider stakeholders require evidence that demonstrates your device or technology’s impact on health and economic outcomes in a defined patient population. As the payment and coverage policy landscapes evolve in the U.S. it is necessary to consider evidence beyond what is required for U.S. regulatory clearance or approval for successful market adoption. Developing and executing an evidence generation plan that spans the product lifecycle is imperative. Hear from Tonya Dowd, Vice President of Reimbursement, Health Economics and Market Access, John McDermott, Senior Director, Reimbursement Strategy, and Abigail Allen, VP of Clinical Affairs, and MCRA’s Life Science Expert Advisory Panel, which consists of payer medical directors and hospital executives, on the need for an evidence generation plan to meet the increasing clinical data requirements for payer stakeholders. This webinar will also discuss how to efficiently execute data collection and reporting.*

- Overview of evolving reimbursement pathways (ie. MCIT) and increasing need for clinical data
- Live Q&A panel session with Payer Medical Directors and Hospital Executives
- Execution of efficient data collection methods

**Tonya Dowd, VP of Reimbursement, Health Economics and Market Access, MCRA**  
**John McDermott, Senior Director, Reimbursement Strategy, MCRA**  
**Abigail Allen, VP of Clinical Affairs, MCRA**  
**Kenneth Strople, President, Fusion Healthcare Management, LLC**  
**John Fox, Chief Boundary Spanner, Foxworthy Healthcare Consulting**

Friday, February 5 - all times in GMT

09:00 1:1 Partnering Continued

1:1 Partnering (24 hours all week)

# Showcases































































# Showcases




**FIRE1**



**MEMMO**  
THERAPEUTICS AG




**ORYZON**



Abarceo Pharma



**Exhaura**



LYDEX PHARMACEUTICALS

# Showcases



FerryX

Orbi Health

Pan Cancer T

Phire Therapeutics

TRINCE



mycoBiologics



# Showcases



MIGRA Therapeutics



# Showcases



# Showcases



# Showcases





# Snapshot of Investors Registered



# Snapshot of Investors Registered



# Industry Leading Events



1-5 February 2021  
Delivered Virtually  
[www.lsxleaders.com/world](http://www.lsxleaders.com/world)



6-10 September 2021  
Delivered Virtually  
[www.lsxleaders.com/nordic](http://www.lsxleaders.com/nordic)



3-6 May 2021  
Delivered Virtually  
[www.longevityleaders.com](http://www.longevityleaders.com)



10-15 November 2021  
Delivered Virtually  
[www.lsxleaders.com/investival](http://www.lsxleaders.com/investival)



11-15 May 2021  
Delivered Virtually  
[www.healthspanshow.com](http://www.healthspanshow.com)

# Pass Benefits

The Congress offers a limited number of opportunities for those that wish to raise their profile, showcase their solutions, enhance their brand, demonstrate thought leadership and access and engage with leaders across the life sciences ecosystem. We are presenting tremendous opportunities for top tier companies who would see the congress as a platform to:

- ✓ Watch all the talks and panel discussions
- ✓ The opportunity to record and deliver an online showcase to raise your company's profile
- ✓ Schedule 1:1 video partnering throughout the event with all attendees
- ✓ Connect with attendees through live chat conversations
- ✓ Join interactive virtual forums with your peers and workshops with industry experts
- ✓ Resources, reports and speaker presentations available for download

To book your place please visit: [www.lsxleaders.com/world](http://www.lsxleaders.com/world)

# Delegate Packages

Tickets	30-Oct-20	20-Nov-20	11-Dec-20	15-Jan-21	Final Price
Content Only (No 1:1 partnering)	Free	Free	Free	Free	Free
Investor	Free	Free	Free	Free	Free
Bio/Health/Med...tech	£695	£845	£945	£945	£1,295
Bio/Health/Med...tech Up to 3 executives + Showcase	£995	£1,195	£1,295	£1,395	£1,695
Large Biotech / Pharma / Commercial Leader Up to 3 executives	£695	£845	£945	£945	£1,295
Large Biotech / Pharma / Commercial Leader Up to 5 executives	£995	£1,195	£1,245	£1,245	£1,695
Professional / Financial / Contract Services	£995	£1,195	£1,245	£1,445	£1,695

To book your place please visit: [www.lsxleaders.com/world](http://www.lsxleaders.com/world)

# Why sponsor

The Congress offers a limited number of opportunities for those that wish to raise their profile, showcase their solutions, enhance their brand, demonstrate thought leadership and access and engage with leaders across the life sciences ecosystem. We are presenting tremendous opportunities for top tier companies who would see the congress as a platform to:

- ✓

Watch all the talks and panel discussions
- ✓

The opportunity to record and deliver an online showcase to raise your company's profile
- ✓

Schedule 1:1 video partnering throughout the event with all attendees
- ✓

Connect with attendees through live chat conversations
- ✓

Join interactive virtual forums with your peers and workshops with industry experts
- ✓

Resources, reports and speaker presentations available for download

For sponsor or exhibition enquiries contact Tom Roberts [tom@lsxleaders.com](mailto:tom@lsxleaders.com)



# Sponsorship Packages


Tickets	Platinum	Gold	Partnering	Showcase	Booth
Presentation (20min)	Yes				
Panel moderator / panellist	Yes	Yes			
Executive forum host	Yes				
Exclusive branding on 1:1 partnering system			Yes		
Exclusive branding on company investment showcases				Yes	
Inclusion in virtual delegate bag	Yes	Yes	Yes		
Personalised ROI data and analytics	Yes	Yes	Yes	Yes	
Targeted sponsor ads	Yes	Yes			
Virtual sponsor booth	Yes	Yes	Yes	Yes	Yes
Pre-event marketing and brand exposure	Yes	Yes	Yes	Yes	Yes
Branding across virtual experience website	Yes	Yes	Yes	Yes	Yes
Number of virtual passes for content and 1:1 partnering	5	4	3	2	2
Investment Level	£££	£££	££	££	£

For sponsor or exhibition enquiries contact Tom Roberts [tom@lsxleaders.com](mailto:tom@lsxleaders.com)

# LSX World Congress 2020 Attendee Breakdown

The 6th LSX World Congress grew significantly this year, in terms of the overall numbers and diversity of the delegation. The international investor attendance was over 300, and we welcomed the most exciting life science and healthcare companies from across the world; from the newest innovative start-ups to leading public corporates.


The following stats represent the diversity of our audience.



# 2020 Investor Breakdown



# 2020 Corporate Breakdown



# Contact Us

---

For biotech and general enquiries contact:

Josh Dance, SVP  
josh@lsxleaders.com  
+44 (0) 203 637 5908

For healthtech and medtech enquiries contact:

Becky Johnson, Conference Director  
becky@lsxleaders.com  
+44 (0) 203 039 3411

For sponsor enquiries contact:

Tom Roberts, VP, Business Development  
tom@lsxleaders.com  
+44 (0) 203 637 5908

Or visit us at [www.lsxleaders.com/world](http://www.lsxleaders.com/world)